These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 15067014)
1. The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. Morgan MR; Thomas GJ; Russell A; Hart IR; Marshall JF J Biol Chem; 2004 Jun; 279(25):26533-9. PubMed ID: 15067014 [TBL] [Abstract][Full Text] [Related]
2. Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Karadag A; Fedarko NS; Fisher LW Cancer Res; 2005 Dec; 65(24):11545-52. PubMed ID: 16357164 [TBL] [Abstract][Full Text] [Related]
3. Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily. A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors. Uekita T; Gotoh I; Kinoshita T; Itoh Y; Sato H; Shiomi T; Okada Y; Seiki M J Biol Chem; 2004 Mar; 279(13):12734-43. PubMed ID: 14718544 [TBL] [Abstract][Full Text] [Related]
4. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Yokosaki Y; Tanaka K; Higashikawa F; Yamashita K; Eboshida A Matrix Biol; 2005 Sep; 24(6):418-27. PubMed ID: 16005200 [TBL] [Abstract][Full Text] [Related]
5. Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. Baum O; Hlushchuk R; Forster A; Greiner R; Clézardin P; Zhao Y; Djonov V; Gruber G Int J Oncol; 2007 Feb; 30(2):325-32. PubMed ID: 17203213 [TBL] [Abstract][Full Text] [Related]
6. Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the beta6 integrin subunit. Niu J; Dorahy DJ; Gu X; Scott RJ; Draganic B; Ahmed N; Agrez MV Int J Cancer; 2002 Jun; 99(4):529-37. PubMed ID: 11992542 [TBL] [Abstract][Full Text] [Related]
7. An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. Ratnikov BI; Rozanov DV; Postnova TI; Baciu PG; Zhang H; DiScipio RG; Chestukhina GG; Smith JW; Deryugina EI; Strongin AY J Biol Chem; 2002 Mar; 277(9):7377-85. PubMed ID: 11741954 [TBL] [Abstract][Full Text] [Related]
8. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. Björklund M; Heikkilä P; Koivunen E J Biol Chem; 2004 Jul; 279(28):29589-97. PubMed ID: 15123665 [TBL] [Abstract][Full Text] [Related]
9. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Giannelli G; Bergamini C; Fransvea E; Marinosci F; Quaranta V; Antonaci S Lab Invest; 2001 Apr; 81(4):613-27. PubMed ID: 11304581 [TBL] [Abstract][Full Text] [Related]
10. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. Stefanidakis M; Bjorklund M; Ihanus E; Gahmberg CG; Koivunen E J Biol Chem; 2003 Sep; 278(36):34674-84. PubMed ID: 12824186 [TBL] [Abstract][Full Text] [Related]
11. Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Thomas GJ; Hart IR; Speight PM; Marshall JF Br J Cancer; 2002 Oct; 87(8):859-67. PubMed ID: 12373600 [TBL] [Abstract][Full Text] [Related]
12. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Sun LC; Luo J; Mackey LV; Fuselier JA; Coy DH Cancer Lett; 2007 Feb; 246(1-2):157-66. PubMed ID: 16644105 [TBL] [Abstract][Full Text] [Related]
13. Glycosylation of the laminin receptor (α3β1) regulates its association with tetraspanin CD151: Impact on cell spreading, motility, degradation and invasion of basement membrane by tumor cells. Ranjan A; Bane SM; Kalraiya RD Exp Cell Res; 2014 Apr; 322(2):249-64. PubMed ID: 24530578 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Ahmed N; Pansino F; Clyde R; Murthi P; Quinn MA; Rice GE; Agrez MV; Mok S; Baker MS Carcinogenesis; 2002 Feb; 23(2):237-44. PubMed ID: 11872628 [TBL] [Abstract][Full Text] [Related]
15. 37-kDa laminin receptor precursor mediates GnRH-II-induced MMP-2 expression and invasiveness in ovarian cancer cells. Poon SL; Klausen C; Hammond GL; Leung PC Mol Endocrinol; 2011 Feb; 25(2):327-38. PubMed ID: 21193558 [TBL] [Abstract][Full Text] [Related]
16. 3-phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. Xie Z; Yuan H; Yin Y; Zeng X; Bai R; Glazer RI BMC Cancer; 2006 Mar; 6():77. PubMed ID: 16551362 [TBL] [Abstract][Full Text] [Related]
17. Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Leroy-Dudal J; Demeilliers C; Gallet O; Pauthe E; Dutoit S; Agniel R; Gauduchon P; Carreiras F Int J Cancer; 2005 Apr; 114(4):531-43. PubMed ID: 15609323 [TBL] [Abstract][Full Text] [Related]
18. The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. Kloeker S; Major MB; Calderwood DA; Ginsberg MH; Jones DA; Beckerle MC J Biol Chem; 2004 Feb; 279(8):6824-33. PubMed ID: 14634021 [TBL] [Abstract][Full Text] [Related]
19. Regulation of cellular invasion and matrix metalloproteinase activity in HepG2 cell by connexin 26 transfection. Yano T; Yamasaki H Mol Carcinog; 2001 Jun; 31(2):101-9. PubMed ID: 11429787 [TBL] [Abstract][Full Text] [Related]
20. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. Karadag A; Ogbureke KU; Fedarko NS; Fisher LW J Natl Cancer Inst; 2004 Jun; 96(12):956-65. PubMed ID: 15199115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]